Drug-drug interactions (DDIs) are often caused by the effects of membrane transporters on drug absorption and disposition in the body. Transporters, such as efflux and uptake, can have significant impacts on a drug’s safety and efficacy — either alone or in conjunction with drugmetabolizing enzymes.
Predicting and understanding DDIs through in vitro studies is vital to gaining insights into their potential causes and consequences. It is therefore necessary that drug developers partner with contract research organizations (CROs) that excel in conducting in vitro studies and generating the required data to determine whether clinical DDI studies are necessary.
